JP2022548902A5 - - Google Patents
Info
- Publication number
- JP2022548902A5 JP2022548902A5 JP2022517339A JP2022517339A JP2022548902A5 JP 2022548902 A5 JP2022548902 A5 JP 2022548902A5 JP 2022517339 A JP2022517339 A JP 2022517339A JP 2022517339 A JP2022517339 A JP 2022517339A JP 2022548902 A5 JP2022548902 A5 JP 2022548902A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cells
- expression construct
- scfv
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962902237P | 2019-09-18 | 2019-09-18 | |
| US62/902,237 | 2019-09-18 | ||
| PCT/US2020/050864 WO2021055349A1 (en) | 2019-09-18 | 2020-09-15 | A method of engineering natural killer-cells to target bcma-positive tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022548902A JP2022548902A (ja) | 2022-11-22 |
| JP2022548902A5 true JP2022548902A5 (enExample) | 2023-09-29 |
Family
ID=74883668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022517339A Pending JP2022548902A (ja) | 2019-09-18 | 2020-09-15 | Ｂｃｍａ陽性腫瘍を標的とするためのナチュラルキラー細胞の操作方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220370500A1 (enExample) |
| EP (1) | EP4031577A4 (enExample) |
| JP (1) | JP2022548902A (enExample) |
| CN (1) | CN114729046A (enExample) |
| AR (1) | AR119990A1 (enExample) |
| TW (1) | TW202124447A (enExample) |
| WO (1) | WO2021055349A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| KR20240021179A (ko) * | 2021-05-14 | 2024-02-16 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 키메라 폴리펩티드 및 사용 방법 |
| IL311837A (en) | 2021-10-20 | 2024-05-01 | Takeda Pharmaceuticals Co | Compositions targeting bcma and methods of use thereof |
| EP4419128A4 (en) * | 2021-10-20 | 2025-10-01 | Univ Texas | NK CELL ENGINEERING WITH CAR CONSTRUCTION WITH OPTIMAL SIGNALING |
| EP4493581A1 (en) * | 2022-03-18 | 2025-01-22 | University of Rochester | Combination therapy for treatment of cancer, methods and systems of delivery thereof |
| WO2024218688A1 (en) * | 2023-04-18 | 2024-10-24 | Board Of Regents, The University Of Texas System | Bcma chimeric antigen receptors and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2766608C2 (ru) * | 2012-04-11 | 2022-03-15 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток |
| HRP20191873T1 (hr) * | 2014-12-12 | 2020-01-24 | Bluebird Bio, Inc. | Kimerni antigenski receptori |
| US10294304B2 (en) * | 2015-04-13 | 2019-05-21 | Pfizer Inc. | Chimeric antigen receptors targeting B-cell maturation antigen |
| US11655452B2 (en) * | 2015-06-25 | 2023-05-23 | Icell Gene Therapeutics Inc. | Chimeric antigen receptors (CARs), compositions and methods of use thereof |
| EP3612210A4 (en) * | 2017-04-19 | 2021-01-27 | Board Of Regents, The University Of Texas System | MANIPULATED ANTIGEN RECEPTORS EXPRESSING IMMUNE CELLS |
| CN117721084A (zh) * | 2017-10-12 | 2024-03-19 | 美商生物细胞基因治疗有限公司 | 靶向多种抗原的复合嵌合抗原受体（cCAR）及其组成和使用方法 |
| CN109468283A (zh) * | 2018-11-30 | 2019-03-15 | 北京美康基免生物科技有限公司 | 一种基于cd19和bcma的双重嵌合抗原受体基因修饰的免疫细胞及其应用 |
| CN109734814A (zh) * | 2019-02-12 | 2019-05-10 | 南京卡提医学科技有限公司 | 具有免疫受体的工程化t细胞治疗癌症的用途 |
-
2020
- 2020-09-15 EP EP20866895.4A patent/EP4031577A4/en not_active Withdrawn
- 2020-09-15 JP JP2022517339A patent/JP2022548902A/ja active Pending
- 2020-09-15 US US17/761,190 patent/US20220370500A1/en not_active Abandoned
- 2020-09-15 WO PCT/US2020/050864 patent/WO2021055349A1/en not_active Ceased
- 2020-09-15 CN CN202080079943.1A patent/CN114729046A/zh active Pending
- 2020-09-17 AR ARP200102578A patent/AR119990A1/es unknown
- 2020-09-18 TW TW109132239A patent/TW202124447A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022548902A5 (enExample) | ||
| JP2022184852A5 (enExample) | ||
| AU2016342560B2 (en) | Receptor | |
| JP2023509766A5 (enExample) | ||
| Colucci et al. | What does it take to make a natural killer? | |
| JP2022550899A5 (enExample) | ||
| EP3564266A1 (en) | Novel chimeric antigen receptor and use thereof | |
| JP6990244B2 (ja) | ヒトｃｄ１２３を標的とするキメラ受容体リガンド及びその応用 | |
| JP2022548943A5 (enExample) | ||
| JP2024519515A5 (enExample) | ||
| CN109280086B (zh) | 一种肿瘤微环境特异性活化的缺氧诱导型嵌合抗原受体 | |
| JP2022542321A5 (enExample) | ||
| JP2024525492A5 (enExample) | ||
| JP2024513906A5 (enExample) | ||
| JP2024525609A5 (enExample) | ||
| KR20210018838A (ko) | 유전자 조작된 세포 및 응용 | |
| AU2018321134B2 (en) | Chimeric antigen receptor and CAR-T cells that bind CXCR5 | |
| JP2023548467A5 (enExample) | ||
| CN111479918A (zh) | 细胞 | |
| JP2025501214A5 (enExample) | ||
| JP2024521566A5 (enExample) | ||
| JP2024527879A5 (enExample) | ||
| JP2024521185A5 (enExample) | ||
| WO2023193660A1 (zh) | 增强型嵌合抗原受体及其应用 | |
| JP2023540551A (ja) | 免疫療法組成物 |